Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia

Anesthesia and Analgesia

Volumn 102, Issue 3, 2006, Pages 738-743

  Imbeault, Karynn ^a   Withington, Davina E ^a   Varin, France ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CEPHALOSPORIN DERIVATIVE; CISATRACURIUM; FENTANYL; HALOTHANE; LAUDANOSINE; LIDOCAINE; MIDAZOLAM; NITROUS OXIDE; OPIATE; PENICILLIN DERIVATIVE; PROPOFOL; TRIMETAPHAN;

ARTICLE; CHILD; CLINICAL ARTICLE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INHALATION ANESTHESIA; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL; VENOUS BLOOD;

EID: 33644540175     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ane.0000195342.29133.ce     Document Type: Article

References (26)

1. Cohen G. Therapeutic orphans, pediatric victims? The Best Pharmaceuticals for Child Act and existing pediatric human subject protection. Food Drug Law J 2003;58:661-710.
2. Bryson HM, Faulds D. Cisatracurium besilate: a review of its pharmacology and clinical potential in anaesthetic practice. Drugs 1997;53:848-66.
3. Meretoja OA, Taivainen T, Wirtavuori K. Cisatracurium during halothane and balanced anaesthesia in children. Paediatr Anaesth 1996;6:373-8.
4. de Ruiter J, Crawford MW. Dose-response relationship and infusion requirement of cisatracurium besylate in infants and children during nitrous oxide-narcotic anesthesia. Anesthesiology 2001;94:790-2.
5. Kenaan CA, Estacio RL, Bikhazi GB. Pharmacodynamics and intubating conditions of cisatracurium in children during halothane and opioid anesthesia. J Clin Anesth 2000;12:173-6.
6. Meretoja OA, Taivainen T, Wirtavuori K. Pharmacodynamic effects of 51W89, an isomer of atracurium, in children during halothane anaesthesia. Br J Anaesth 1995;74:6-11.
7. Brandom BW, Woelfel SK, Ference A, et al. Effects of cisatracurium in children during halothane-nitrous oxide anesthesia. J Clin Anesth 1998;10:195-9.
8. Lepage JY, Malinovsky JM, Malinge M, et al. Pharmacodynamic dose-response and safety study of cisatracurium (51W89) in adult surgical patients during N2O-O2-opioid anesthesia. Anesth Analg 1996;83:823-9.
9. Bergeron L, Bevan DR, Berrill A, et al. Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. Anesthesiology 2001;95:314-23.
10. Tran TV, Fiset P, Varin F. Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. Anesth Analg 1998;87:1158-63.
11. Belmont MR, Lien CA, Quessy S, et al. The clinical neuromuscular pharmacology of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 1995;82:1139-45.
12. Dragne A, Varin F, Plaud B, Donati F. Rocuronium pharmacokinetic- pharmacodynamic relationship under stable propofol or isoflurane anesthesia. Can J Anaesth 2002;49:353-60.
13. Bryant BJ, James CD, Cook DR, Harrelson JC. High performance liquid chromatography assay for cisatracurium and its metabolites in human urine. J Li Qchrom Rel Technol 1997;20:2041-51.
14. Ludden TM, Beal SL, Sheiner LB. Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection. J Pharmacokinet Biopharm 1994;22:431-15.
15. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165-75.
16. Nakashima E, Benet LZ. General treatment of mean residence time, clearance, and volume parameters in linear mammillary models with elimination from any compartment. J Pharmacokinet Biopharm 1988;16:475-92.
17. Welch RM, Brown A, Ravitch J, Dahl R. The in vitro degradation of cisatracurium, the R, cis-R′-isomer of atracurium, in human and rat plasma. Clin Pharmacol Ther 1995;58:132-42.
18. Soltesz S, Silomon M, Mencke T, et al. Neuromuscular blockade with cisatracurium in infants and children: its course under sevoflurane anesthesia [in German]. Anaesthesist 2002;51:374-7.
19. Taivainen T, Meakin GH, Meretoja OA, et al. The safety and efficacy of cisatracurium 0.15 mg.kg(-1) during nitrous oxide-opioid anaesthesia in infants and children. Anaesthesia 2000;55:1047-51.
20. Brandom BW, Westman HR. Effects of 0.86 mg/kg cisatracurium in an infant. Anesthesiology 1996;85:688-9.
21. Kisor DF, Schmith VD, Wargin WA, et al. Importance of the organ-independent elimination of cisatracurium. Anesth Analg 1996;83:1065-71.
22. Schmith VD, Fiedler-Kelly J, Phillips L, Grasela TH Jr. Dose proportionality of cisatracurium. J Clin Pharmacol 1997;37:625-9.
23. Fisher DM, Canfell PC, Spellman MJ, Miller RD. Pharmacokinetics and pharmacodynamics of atracurium in infants and children. Anesthesiology 1990;73:33-7.
24. Brandom BW, Stiller RL, Cook DR, et al. Pharmacokinetics of atracurium in anaesthetized infants and children. Br J Anaesth 1986;58:1210-3.
25. Ezzine S, Donati F, Varin F. Mivacurium arteriovenous gradient during steady state infusion in anesthetized patients. Anesthesiology 2002;97:622-9.
26. Donati F, Varin F, Ducharme J, et al. Pharmacokinetics and pharmacodynamics of atracurium obtained with arterial and venous blood samples. Clin Pharmacol Ther 1991;49:515-22.